CBL & ASSOCIATES PROPERTIES, INC... CBL Center ... CBL Center, Suite 500 ... CBL & Associates Properties, Inc ... federal income tax considerations applicable solely to our investment in the Operating Partnership through CBL Holdings I and CBL Holdings II.
Attenuation of Post–Discontinuation WeightRegain — The newly disclosed OI25 animal study confirmed that CBL–514 combined with GLP–1R–based therapies achieved superior weight loss compared to monotherapy ... CBL–514 combination group ... About CBL-514.
Both global pivotal Phase 3 studies, CBL-0301 and CBL-0302, are expected to begin patient enrollment shortly, with topline results anticipated in 2027 to support a future New Drug Application (NDA).
CBL-514, when combined separately with two ... The presentation also marked the first disclosure at an international congress of CBL-514's potential to improve liver metabolic indicators ... About CBL-514.